Background - Glioblastoma and MDNA55 The interleukin-4 receptor–targeted immunotherapeutic MDNA55 has demonstrated improved survival and disease control in patients with recurrent Glioblastoma who are treated at high dose, irrespective of…
Background A Phase 2 multi-center study was conducted to evaluate the virus, DNX-240, also called Tasadenoturev, in combination with the immunotherapy, Keytruda, in pateints with recurrent glioblastoma. Methods Patients with…
Background Anthracyclines is a class of drugs used in cancer chemotherapy. A wildly used Anthracycline drug is Doxorubicin also known as Adriamycin. These drugs are used to treat many cancers,…
Background This clinical trial assessed the efficacy and safety of Camrelizumab plus Rivoceranib in patients with advanced liver cancer. Camrelizumab is anti-PD-1 immunotherapy drug given intravenous. Rivoceranib, also known as…
Background - Colorectal cancer and coffee Several compounds found in coffee possess antioxidant, anti-inflammatory and insulin-sensitizing effects, which may contribute to anticancer activity, including colorectal cancer. Epidemiological studies have identified…
Background Concurrent chemoradiation therapy remains the standard therapy for unresectable Esophageal Squamous Cell Carcinoma patients. However, its feasibility and efficiency for older patients are being challenged. Serious acute toxic effects,…
Introduction On October 2nd 2020, the FDA approved Opdivo (Nivolumab) in combination with Yervoy (Ipilimumab) for the first-line treatment of patients with Malignant Pleural Mesothelioma that cannot be removed by…
Background DNA damage is the fundamental cause of cancer – leading to mutations in key genes that allow cancer cells to divide uncontrollably. But it can also be a key…
Background 3-year follow-up results from the randomized phase II study assessing the efficacy and safety of Debio 1143 in combination with chemo-radiation therapy vs. chemo-radiation therapy alone. The treatment was…
Background Breast cancer affects one in eight women. Around 80% are categorized as estrogen receptor-positive, or ER-positive. This means the cancer cells have receptors - molecules that can receive signals…